Holen Sie sich die Stockscreener-App
7.935
3.90%
0.245
Schlusskurs vom Vortag:
$7.69
Offen:
$7.6
24-Stunden-Volumen:
147.16K
Relative Volume:
1.38
Marktkapitalisierung:
$343.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.65M
KGV:
-1.7831
EPS:
-4.45
Netto-Cashflow:
$-20.83M
1W Leistung:
+32.95%
1M Leistung:
+27.43%
6M Leistung:
+266.51%
1J Leistung:
+393.21%
1-Tages-Spanne:
$7.555
$8.03
1-Wochen-Bereich:
$6.00
$8.56
52-Wochen-Spanne:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
7.935 | 332.78M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.15 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.29 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.29 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.73 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Fed Meeting: Can Minerva Neurosciences Inc continue delivering strong returnsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen - MarketBeat
Is Minerva Neurosciences Inc. in a consolidation phaseMarket Weekly Review & Risk Controlled Swing Alerts - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
Weekly Earnings: Can Minerva Neurosciences Inc be recession proofTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. stock showing strong momentumGold Moves & Fast Moving Trade Plans - mfd.ru
Balyasny Asset Management L.P. Acquires Significant Stake in Min - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Minerva Neurosciences Inc. - GuruFocus
Minerva Neurosciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Is Minerva Neurosciences Inc. in a long term uptrendTake Profit & Safe Entry Zone Tips - mfd.ru
Aug Swings: What drives MODVs stock priceJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Balyasny discloses 4.33M-share Minerva Neurosciences (NERV) position - Stock Titan
Is Minerva Neurosciences Inc. stock attractive for growth ETFs2025 Growth vs Value & Accurate Buy Signal Notifications - mfd.ru
Minerva Neurosciences (NERV) to Release Earnings on Tuesday - MarketBeat
Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance
Will Minerva Neurosciences Inc. (4MNA) stock see valuation expansionWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Minerva Neurosciences Expands Board Amid Fundraising Effort - MSN
Market Wrap: Can Minerva Neurosciences Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
How Minerva Neurosciences Inc. (4MNA) stock valuation compares with sectorWeekly Investment Summary & Scalable Portfolio Growth Methods - mfd.ru
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia - MarketBeat
Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone - TipRanks
Buyout Rumor: Is Minerva Neurosciences Inc subject to activist investor interest2025 Trading Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. subject to activist investor interestRate Cut & Reliable Momentum Entry Alerts - mfd.ru
Stock Analysis: Can Minerva Neurosciences Inc be recession proofJuly 2025 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Can Minerva Neurosciences Inc. stock double in the next yearJuly 2025 PreEarnings & Community Consensus Picks - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Can Minerva Neurosciences Inc. stock outperform in a bear marketJuly 2025 Weekly Recap & Weekly Top Performers Watchlists - mfd.ru
Minerva Neurosciences to Host Virtual KOL Event to Discuss - GlobeNewswire
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - Yahoo Finance
Highs Report: Is Minerva Neurosciences Inc trading at a discountJuly 2025 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):